Cannabis Lozenges for Chronic Pain: Evidence and Dose

Cannabis lozenges for chronic pain: the short answer

A cannabis lozenge is a tablet that dissolves in the mouth. It carries THC, CBD, or both. No cannabis lozenge holds FDA approval for chronic pain. Evidence on lozenges is small. Most pain data comes from capsules, oral sprays, and inhaled flower. Reviews of those products report pain relief with small effect sizes. Several guidelines advise against cannabinoids as a first-line pain treatment.

What a lozenge contains

THC: 2.5 mg to 10 mg per lozenge in most state-legal products.
CBD: 5 mg to 50 mg. Some products list 100 mg.
Base: sugar, gelatin, pectin, or glycerin.
Labels in legal US states list THC and CBD content per unit. Lab testing rules differ by state.

How the body handles a lozenge

Two routes. Some drug crosses the lining of the mouth into the blood. The rest is swallowed and passes through the liver. Oral THC bioavailability is 6% to 20%. Inhaled THC is 10% to 35%. Sublingual uptake starts in 15 to 45 minutes. Swallowed THC peaks at 1 to 2 hours. Effects last 4 to 8 hours. A fatty meal before a swallowed dose raises absorption.

cannabis lozenges for chronic pain

Evidence on cannabinoids and chronic pain

A 2017 National Academies review found conclusive evidence that cannabis relieves chronic pain in adults. That review covered smoked and oral products. A 2021 task force from the International Association for the Study of Pain found evidence insufficient for most pain types. A 2018 Cochrane review of neuropathic pain found low-quality evidence and small effects. Trials used nabiximols, nabilone, and dronabinol. None tested a commercial lozenge. Lozenges appear in trials as a delivery format, not as a studied drug.

Start at 2.5 mg THC or less with no tolerance.
Wait 2 hours before a second dose. Swallowed THC keeps rising after the first hour.
Raise by 2.5 mg steps. Space steps by 3 to 7 days.
Keep a log of dose, time, and pain score.

CBD doses in pain trials ran 10 mg to 50 mg per day, and higher. CBD at 200 mg or more can raise liver enzymes. That risk is higher with valproate or clobazam.

cannabis lozenges for chronic pain

Risks

Impairment: driving and machine work are unsafe for 4 to 8 hours.
Dizziness, dry mouth, fast heart rate, and low blood pressure.
Cannabis use disorder affects about 9% of adults who use cannabis. The rate is higher for people who start in their teens.
CBD blocks CYP2C19 and CYP3A4. It can raise levels of warfarin, clopidogrel, and some seizure drugs.
Smoked cannabis is linked to bronchitis. Lozenges avoid smoke.

Unknowns

No head-to-head trial compares lozenges with capsules or inhaled products. The dose response for pain relief is not mapped. Data past 12 months is sparse. Product labels in many states list total cannabinoids, not dissolution rate.